This phase III randomized, double-blind, placebocontrolled study concludes that sorafenib prolongs progression-free survival in patients with advanced clearcell renal-cell carcinoma in whom previous therapy has failed. However, treatment is associated with increased toxic effects. This phase III multicenter, randomized trial demonstrates that progression-free survival was longer and response rates were higher in patients with metastatic renal-cell carcinoma who received sunitinib than in those receiving interferon alfa. The authors analyzed published reports from 1985 to 2006 dealing with the treatment of muscle invasive (stage T2-T4a) bladder cancer. They concluded that the optimal curative strategy in most patients presenting with muscle invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy and complete pelvic lymph node dissection. Duke University Medical Center investigators reported an overall cost advantage in favor of cryosurgical ablation of the prostate. These advantages included the absence of pathologic costs and the need for blood transfusion.
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